Why Did Genmab A/S Shares Soar 13.1% Despite Mixed Analyst Signals?
Mover TrackerFriday, May 16, 2025 8:35 am ET

Genmab A/S shares surged 13.1% in pre-market trading on May 16, 2025, driven by a mix of positive and negative signals from analysts and market trends.
Analysts at H.C. Wainwright adjusted their outlook on
A/S, lowering the 12-month price target to $35 from the previous $37. This adjustment came following the company's Q1 report, which kept a Buy rating on the shares.Despite the price target reduction, the consensus among analysts remains relatively bullish. The average target price for Genmab A/S is $30.72, with a high estimate of $45.00. Additionally,
lowered its target price for Genmab to DKK 2,600 from DKK 2,700, while reiterating a Buy recommendation.MarketBeat.com data indicates that Genmab A/S has a consensus rating of "Moderate Buy" and a consensus target price of $39.17. This suggests that while there are concerns about the stock's performance, many analysts still see potential for growth.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet